These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 31895608)

  • 1. Patient-Reported Functional Outcomes After Hypofractionated or Conventionally Fractionated Radiation for Prostate Cancer: A National Cohort Study in England.
    Nossiter J; Sujenthiran A; Cowling TE; Parry MG; Charman SC; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    J Clin Oncol; 2020 Mar; 38(7):744-752. PubMed ID: 31895608
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Toxicity of Pelvic Lymph Node Irradiation With Intensity Modulated Radiation Therapy for High-Risk and Locally Advanced Prostate Cancer: A National Population-Based Study Using Patient-Reported Outcomes.
    Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Int J Radiat Oncol Biol Phys; 2020 Dec; 108(5):1196-1203. PubMed ID: 32717261
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quality of life in men living with advanced and localised prostate cancer in the UK: a population-based study.
    Downing A; Wright P; Hounsome L; Selby P; Wilding S; Watson E; Wagland R; Kind P; Donnelly DW; Butcher H; Catto JWF; Cross W; Mason M; Sharp L; Weller D; Velikova G; McCaughan E; Mottram R; Allen M; Kearney T; McSorley O; Huws DW; Brewster DH; McNair E; Gavin A; Glaser AW
    Lancet Oncol; 2019 Mar; 20(3):436-447. PubMed ID: 30713036
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
    Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial.
    Fransson P; Nilsson P; Gunnlaugsson A; Beckman L; Tavelin B; Norman D; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Zackrisson B; Kjellén E; Franzén L; Widmark A
    Lancet Oncol; 2021 Feb; 22(2):235-245. PubMed ID: 33444529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Patient-Reported Outcomes Through 5 Years for Active Surveillance, Surgery, Brachytherapy, or External Beam Radiation With or Without Androgen Deprivation Therapy for Localized Prostate Cancer.
    Hoffman KE; Penson DF; Zhao Z; Huang LC; Conwill R; Laviana AA; Joyce DD; Luckenbaugh AN; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Koyama T; Barocas DA
    JAMA; 2020 Jan; 323(2):149-163. PubMed ID: 31935027
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of Treatment-Related Toxicity With Hypofractionated or Conventionally Fractionated Radiation Therapy for Prostate Cancer: A National Population-Based Study.
    Sujenthiran A; Parry M; Nossiter J; Berry B; Cathcart PJ; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Clin Oncol (R Coll Radiol); 2020 Aug; 32(8):501-508. PubMed ID: 32143901
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association Between Radiation Therapy, Surgery, or Observation for Localized Prostate Cancer and Patient-Reported Outcomes After 3 Years.
    Barocas DA; Alvarez J; Resnick MJ; Koyama T; Hoffman KE; Tyson MD; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF
    JAMA; 2017 Mar; 317(11):1126-1140. PubMed ID: 28324093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Hypofractionated Radiation Therapy Use and Patient-Reported Outcomes in Men With Nonmetastatic Prostate Cancer in Australia and New Zealand.
    Pryor DI; Martin JM; Millar JL; Day H; Ong WL; Skala M; FitzGerald LM; Hindson B; Higgs B; O'Callaghan ME; Syed F; Hayden AJ; Turner SL; Papa N
    JAMA Netw Open; 2021 Nov; 4(11):e2129647. PubMed ID: 34724555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Association between pelvic nodal radiotherapy and patient-reported functional outcomes through 5 years among men undergoing external-beam radiotherapy for prostate cancer: An assessment of the comparative effectiveness analysis of surgery and radiation (CEASAR) cohort.
    Wallis CJD; Huang LC; Zhao Z; Penson DF; Koyama T; Conwill R; Tallman JE; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg MR; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Barocas DA; Hoffman KE
    Urol Oncol; 2022 Feb; 40(2):56.e1-56.e8. PubMed ID: 34154899
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
    Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Patient-reported Outcomes After External Beam Radiation Therapy and Combined External Beam With Low-dose-rate Brachytherapy Boost in Men With Localized Prostate Cancer.
    Lee DJ; Barocas DA; Zhao Z; Huang LC; Resnick MJ; Koyoma T; Conwill R; McCollum D; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Kaplan SH; Paddock LE; Stroup AM; Wu XC; Penson DF; Hoffman KE
    Int J Radiat Oncol Biol Phys; 2018 Sep; 102(1):116-126. PubMed ID: 30102188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Patient-reported functional outcomes following external beam radiation therapy for prostate cancer with and without a high-dose rate brachytherapy boost: A national population-based study.
    Parry MG; Nossiter J; Cowling TE; Sujenthiran A; Berry B; Cathcart P; Clarke NW; Payne H; van der Meulen J; Aggarwal A
    Radiother Oncol; 2021 Feb; 155():48-55. PubMed ID: 33075390
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Robot-assisted radical prostatectomy vs laparoscopic and open retropubic radical prostatectomy: functional outcomes 18 months after diagnosis from a national cohort study in England.
    Nossiter J; Sujenthiran A; Charman SC; Cathcart PJ; Aggarwal A; Payne H; Clarke NW; van der Meulen J
    Br J Cancer; 2018 Feb; 118(4):489-494. PubMed ID: 29348490
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiotherapy after radical prostatectomy: Effect of timing of postprostatectomy radiation on functional outcomes.
    Huelster HL; Laviana AA; Joyce DD; Huang LC; Zhao Z; Koyama T; Hoffman KE; Conwill R; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; Cooperberg M; Hashibe M; O'Neil BB; Kaplan SH; Greenfield S; Penson DF; Barocas DA
    Urol Oncol; 2020 Dec; 38(12):930.e23-930.e32. PubMed ID: 32736934
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Prostate Cancer Severity on Functional Outcomes After Localized Treatment: Comparative Effectiveness Analysis of Surgery and Radiation Study Results.
    Tyson MD; Koyama T; Lee D; Hoffman KE; Resnick MJ; Wu XC; Cooperberg MR; Goodman M; Greenfield S; Hamilton AS; Hashibe M; Paddock LE; Stroup A; Chen V; Conwill R; McCollum D; Penson DF; Barocas DA
    Eur Urol; 2018 Jul; 74(1):26-33. PubMed ID: 29501451
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Is Ultrahypofractionated Whole Pelvis Radiation Therapy (WPRT) as Well Tolerated as Conventionally Fractionated WPRT in Patients With Prostate Cancer? Early Results From the HOPE Trial.
    Mendez LC; Crook J; Martell K; Schaly B; Hoover DA; Dhar A; Velker V; Ahmad B; Lock M; Halperin R; Warner A; Bauman GS; D'Souza DP
    Int J Radiat Oncol Biol Phys; 2024 Jul; 119(3):803-812. PubMed ID: 38072323
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Conventional Versus Hypofractionated Radiation for High-Risk Prostate Cancer Patients (CHIRP): 24-Month Patient-Reported Outcomes of the Randomized Phase 2 CHIRP Trial.
    Yang F; Ghosh S; Yee D; Patel S; Pervez N; Parliament M; Usmani N; Danielson B; Amanie J; Pearcey R; Field C; Fallone G; Murtha A
    Int J Radiat Oncol Biol Phys; 2022 Sep; 114(1):99-107. PubMed ID: 35537578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.